Search

Author/Creator Puhlmann, M.

1. P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B). (23rd June 2022)

Authors:
Lee, H.; Flinn, I. W.; Melear, J.; Ramchandren, R.; Friedman, J.; Burke, J. M.; Linhares, Y.; Raval, M.; Chintapatla, R.; Feldman, T. A.; Yimer, H.; Islas-Ohlmayer, M.; Dean, A.; Rana, V.; Gandhi, M. D.; Renshaw, J.; Gillespie-Twardy, A. L.; Ho, L.; Puhlmann, M.; Guo, W.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
979
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study. (February 2017)

Authors:
Necchi, A.; Bellmunt, J.; De Wit, R.; Vaughn, D.; Fradet, Y.; Lee, J.L.; Fong, L.; Vogelzang, N.; Climent, M.; Petrylak, D.; Choueiri, T.; Gerritsen, W.; Gurney, H.; Quinn, D.; Culine, S.; Sternberg, C.; Mai, Y.; Puhlmann, M.; Perini, R.; Bajorin, D.
Journal:
European journal of cancer
Issue:
Volume 72(2017)Supplement 1
Page Start:
S2
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1. (23rd June 2022)

Authors:
Hutchings, M.; Ansell, S. M.; Straus, D. J.; Connors, J. M.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R.; Evens, A. M.; Smolewski, P.; Savage, K. J.; Bartlett, N. L.; Eom, H.-S.; Abramson, J. S.; Dong, C.; Campana, F.; Fenton, K.; Puhlmann, M.; Radford, J.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
101
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search